BR112021025943A2 - Innovative tumor-specific antigens for ovarian cancer and uses thereof - Google Patents
Innovative tumor-specific antigens for ovarian cancer and uses thereofInfo
- Publication number
- BR112021025943A2 BR112021025943A2 BR112021025943A BR112021025943A BR112021025943A2 BR 112021025943 A2 BR112021025943 A2 BR 112021025943A2 BR 112021025943 A BR112021025943 A BR 112021025943A BR 112021025943 A BR112021025943 A BR 112021025943A BR 112021025943 A2 BR112021025943 A2 BR 112021025943A2
- Authority
- BR
- Brazil
- Prior art keywords
- ovarian cancer
- tsas
- hgsc
- specific antigens
- innovative
- Prior art date
Links
- 206010061535 Ovarian neoplasm Diseases 0.000 title abstract 6
- 206010033128 Ovarian cancer Diseases 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000008595 infiltration Effects 0.000 abstract 1
- 238000001764 infiltration Methods 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Abstract
antígenos específicos de tumor inovadores para câncer de ovário e usos dos mesmos. o câncer de ovário, particularmente o câncer de ovário seroso de alto grau (hgsc), que é a principal causa de morte por malignidades ginecológicas no mundo, não se beneficiou significativamente do progresso recente na imunoterapia contra o câncer. embora a infiltração de hgsc por linfócitos se correlacione com a sobrevivência superior, a natureza dos antígenos que podem desencadear respostas imunes anti-hgsc é desconhecida. antígenos específicos de tumor (tsas) inovadores compartilhados por uma grande proporção de tumores ovarianos são descritos no presente documento. a maioria dos tsas (> 80%) aqui descritos deriva de sequências genômicas não mutadas expressas de forma aberrante, tais como sequências intrônicas e intergênicas, que não são expressas em tecidos normais. são descritos ácidos nucleicos, composições, células e vacinas derivadas desses tsas. o uso dos tsas, ácidos nucleicos, composições, células e vacinas para o tratamento de câncer de ovário também é descrito.innovative tumor-specific antigens for ovarian cancer and uses thereof. Ovarian cancer, particularly high-grade serous ovarian cancer (hgsc), which is the leading cause of death from gynecologic malignancies worldwide, has not benefited significantly from recent progress in cancer immunotherapy. although infiltration of hgsc by lymphocytes correlates with superior survival, the nature of the antigens that can trigger anti-hgsc immune responses is unknown. Innovative tumor-specific antigens (tsas) shared by a large proportion of ovarian tumors are described herein. most of the tsas (>80%) described here are derived from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, that are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these tsas are described. the use of the tsas, nucleic acids, compositions, cells and vaccines for the treatment of ovarian cancer is also described.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962866089P | 2019-06-25 | 2019-06-25 | |
PCT/CA2020/050869 WO2020257922A1 (en) | 2019-06-25 | 2020-06-22 | Novel tumor-specific antigens for ovarian cancer and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021025943A2 true BR112021025943A2 (en) | 2022-02-08 |
Family
ID=74059840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021025943A BR112021025943A2 (en) | 2019-06-25 | 2020-06-22 | Innovative tumor-specific antigens for ovarian cancer and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220354937A1 (en) |
EP (1) | EP3990483A4 (en) |
JP (1) | JP2022539301A (en) |
KR (1) | KR20220025808A (en) |
CN (1) | CN114026117A (en) |
AU (1) | AU2020301838A1 (en) |
BR (1) | BR112021025943A2 (en) |
CA (1) | CA3141898A1 (en) |
IL (1) | IL288826A (en) |
MX (1) | MX2022000046A (en) |
SG (1) | SG11202113192QA (en) |
WO (1) | WO2020257922A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020041876A1 (en) | 2018-08-30 | 2020-03-05 | Université de Montréal | Proteogenomic-based method for identifying tumor-specific antigens |
WO2023023840A1 (en) * | 2021-07-16 | 2023-03-02 | Université de Montréal | Novel tumor-specific antigens for cancer stem cells and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003111595A (en) * | 2001-06-25 | 2003-04-15 | Kyogo Ito | Tumor antigen |
EP3777882A1 (en) * | 2013-07-30 | 2021-02-17 | BioNTech SE | Tumor antigens for determining cancer therapy |
GB201511191D0 (en) * | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
GB201512369D0 (en) * | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
GB201517538D0 (en) * | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
GB201604490D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
MA47367B1 (en) * | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | NOVEL PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS |
BR112021026375A2 (en) * | 2019-06-28 | 2022-05-10 | Enara Bio Ltd | Innovative cancer antigens and methods |
-
2020
- 2020-06-22 US US17/622,552 patent/US20220354937A1/en active Pending
- 2020-06-22 BR BR112021025943A patent/BR112021025943A2/en unknown
- 2020-06-22 JP JP2021572500A patent/JP2022539301A/en active Pending
- 2020-06-22 CA CA3141898A patent/CA3141898A1/en active Pending
- 2020-06-22 MX MX2022000046A patent/MX2022000046A/en unknown
- 2020-06-22 WO PCT/CA2020/050869 patent/WO2020257922A1/en unknown
- 2020-06-22 KR KR1020227001272A patent/KR20220025808A/en unknown
- 2020-06-22 SG SG11202113192QA patent/SG11202113192QA/en unknown
- 2020-06-22 CN CN202080046241.3A patent/CN114026117A/en active Pending
- 2020-06-22 AU AU2020301838A patent/AU2020301838A1/en active Pending
- 2020-06-22 EP EP20832110.9A patent/EP3990483A4/en active Pending
-
2021
- 2021-12-09 IL IL288826A patent/IL288826A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020257922A1 (en) | 2020-12-30 |
EP3990483A1 (en) | 2022-05-04 |
JP2022539301A (en) | 2022-09-08 |
MX2022000046A (en) | 2022-02-24 |
AU2020301838A1 (en) | 2022-02-10 |
SG11202113192QA (en) | 2021-12-30 |
US20220354937A1 (en) | 2022-11-10 |
IL288826A (en) | 2022-02-01 |
CA3141898A1 (en) | 2020-12-30 |
CN114026117A (en) | 2022-02-08 |
KR20220025808A (en) | 2022-03-03 |
EP3990483A4 (en) | 2024-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021025943A2 (en) | Innovative tumor-specific antigens for ovarian cancer and uses thereof | |
HRP20210766T1 (en) | Indoleamine 2, 3-dioxygenase based immunotherapy | |
BR112018076027A2 (en) | method for modifying a target sequence in the genome of a plant cell; method for editing a nucleotide sequence in the genome of a plant cell; method for simultaneously modifying multiple target sequences in the genome of a plant cell; method for modifying a DNA target sequence in a plant cell genome and polynucleotide modification model | |
Na et al. | Hypermethylation of growth arrest DNA-damage-inducible gene 45 in non-small cell lung cancer and its relationship with clinicopathologic features | |
WO2016036994A8 (en) | Method of analysis allowing avoidance of surgery | |
CY1122074T1 (en) | NEW 2' AND/OR 5' AMINO ACID 3'-DEOXYADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | |
PE20181538A1 (en) | NEW IMMUNOTHERAPY AGAINST VARIOUS TUMORS SUCH AS LUNG CANCER, INCLUDING AMICROCITIC LUNG CARCINOMA (NSCLC) | |
AR049188A1 (en) | ADENOVIRUS CHEMICALS FOR USE IN THE TREATMENT OF CANCER | |
MX2023001945A (en) | Compositions and methods for screening solid tumors. | |
PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
NO20055708L (en) | Synthetic gene encoding human carcinoma embryonic antigen and uses thereof | |
WO2018234506A3 (en) | Personalized vaccine | |
MX2019003546A (en) | Optimized oncolytic viruses and uses thereof. | |
Gokul et al. | DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer | |
BR112022020376A2 (en) | TUMOR-SPECIFIC ANTIGENS FOR ACUTE MYELOID LEUKEMIA (AML) AND USES THEREOF | |
UA113413C2 (en) | Mphosph1 peptides and vaccines including the same | |
Turhal et al. | Prevalence of K-Ras mutations in hepatocellular carcinoma: AA Turkish Oncology Group pilot study | |
Carrozza et al. | Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors | |
AR081065A1 (en) | ECT2 PEPTIDES (EPITELIAL CELL TRANSFORMATION SEQUENCE 2) AND VACCINES THAT INCLUDE THEM | |
WO2020023776A3 (en) | Compositions and methods for inhibiting cancers and viruses | |
Zak et al. | Aspp1: a guardian of hematopoietic stem cell integrity | |
EP2545171A4 (en) | Hjurp peptides and vaccines including the same | |
Tahover | An exceptional response to immunotherapy doublet in combined hepatocellular carcinoma-cholangiocarcinoma | |
Bernig et al. | Functional analysis and molecular characterization of spontaneously outgrown human lymphoblastoid cell lines | |
Mbaye et al. | Genetic diversity of breast cancer in senegalese women: new insight from somatic mutations |